Abstract
Pancreas adenocarcinoma is now the 10th-leading cause of cancer in the United States but the fourth leading cause of cancer-related death. By 2030, it is expected to be the second-leading cause of cancer-related death in the United States after lung cancer. Understanding the genetics, molecular biology, and immunology of pancreas cancer has been key to making inroads in developing new therapies. This chapter highlights recent progress.
Original language | English (US) |
---|---|
Title of host publication | Abeloff’s Clinical Oncology |
Publisher | Elsevier |
Pages | 1342-1360.e7 |
ISBN (Electronic) | 9780323476744 |
DOIs | |
State | Published - Jan 1 2019 |
Keywords
- FOLFIRINOX
- Gemcitabine and abraxane
- Mismatch repair deficiency
- Progression model
- Tumor micro environment
ASJC Scopus subject areas
- General Medicine